Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 10 years of age or older~* Documented diagnosis of HAE (Type I or II)~* Willing and able to give informed consent~* Acute HAE attack at time of presentation~Exclusion Criteria:~* Receipt of an investigational drug or device, within 30 days prior to study treatment, other than DX-88 (ecallantide)~* Pregnancy or breastfeeding~* Receipt of non-investigational C1-INH or DX-88 within 72 hours of treatment~* Patients eligible for current, ongoing clinical trial in which DX 88 (ecallantide) is offered

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DX-88 (ecallantide) (Type: EXPERIMENTAL): DX-88 (ecallantide) Patients were treated with DX-88 (ecallantide) when they experienced an HAE attack. 30 mg dose of ecallantide given via 3 SC injections; a second 30 mg dose can be administered if needed. Patients were to be assessed until 4 hrs post-dose. Patients were asked to return for 3 follow-up visits: 7 days, 28 days and 90 days post-dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).